Verition Fund Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Verition Fund Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,500	Closed	-$604K	–	3747
2024 Q4	$604K	Sell	1,500 -1,200	-44%	-$556K	﹤0.01%	2364
2024 Q3	$1.26M	Sell	2,700 -300	-10%	-$144K	0.01%	1729
2024 Q2	$1.41M	Buy	3,000 +400	+15%	+$174K	0.01%	1472
2024 Q1	$1.09M	Sell	2,600 -23,000	-90%	-$9.72M	0.01%	1573
2023 Q4	$10.4M	Hold	25,600	–	–	0.08%	225
2023 Q3	$8.9M	Buy	25,600 +25,000	+4,167%	+$8.74M	0.1%	253
2023 Q2	$211K	Buy	+600	New	+$202K	﹤0.01%	1816
2023 Q1	–	Sell	-20,800	Closed	-$6.01M	–	2583
2022 Q4	$6.01M	Hold	20,800	–	–	0.09%	268
2022 Q3	$6.02M	Buy	+20,800	New	+$5.98M	0.07%	352
2022 Q2	–	Sell	-23,400	Closed	-$6.11M	–	3093
2022 Q1	$6.11M	Buy	23,400 +2,600	+13%	+$617K	0.07%	300
2021 Q4	$4.57M	Buy	20,800 +800	+4%	+$156K	0.03%	404
2021 Q3	$3.63M	Buy	+20,000	New	+$3.9M	0.03%	370

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Verition Fund Management's VRTX Position: Q1 2026 in Review

Verition Fund Management reduced its Vertex Pharmaceuticals (VRTX) stake by 83% in Q1 2026, selling an estimated $3.26M and leaving 1,409 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #1505.

Verition Fund Management first reported a position in VRTX in Q3 2014 and has held it in 35 quarters since. The position peaked at $16.6M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Verition Fund Management held 1,409 shares of Vertex Pharmaceuticals worth $629K as of Q1 2026.
Verition Fund Management sold 6,997 Vertex Pharmaceuticals shares in Q1 2026, an estimated $3.26M.
Vertex Pharmaceuticals made up ﹤0.01% of Verition Fund Management's portfolio in Q1 2026, its #1505 holding.
Verition Fund Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and has held it in 35 quarters since.
Verition Fund Management's Vertex Pharmaceuticals position peaked at $16.6M in Q3 2022.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.